The hematoxylin and eosin (H&E) stain has long been an essential tool in the pathologist’s arsenal. Positively-charged hematoxylin and negatively-charged eosin bind to different substances within a tissue sample. This allows pathologists to clearly view
Athena, a voice for professional women in STEM in Southern California, recently became a signatory of the United Nations Global Compact. Athena joins over 9,933 companies in 160 countries focused on aligning their strategies and
Orthotopic Patient-Derived Xenografts (PDX) Despite the rise of personalized approaches to the treatment of cancer, translating these therapies into a clinical setting still poses an exceptional challenge. This is highlighted in drug development where research
SAN DIEGO, AUGUST 13, 2018. (GLOBE NEWSWIRE). Certis Oncology Solutions and Reveal Biosciences today announced a strategic partnership in which the two companies will collaborate to provide an innovative, next-generation suite of pre-clinical oncology services.
PALO ALTO, Calif.–(BUSINESS WIRE)–Science Exchange, the leading marketplace for outsourced R&D™, announces a collaboration with Reveal Biosciences to offer on-demand access to AI-based pathology services worldwide. Reveal Biosciences is a San Diego-based company that’s leading the next generation
CASE STUDY Cancer R&D researchers have adopted the use of immunohistochemistry (IHC) tests for research, prognostic and diagnostic use at an extremely fast rate (1). Despite these statistics, many antibody vendors targeting these researchers do
CASE STUDY Researchers have adopted the use of immunohistochemistry (IHC) tests for research, prognostic and diagnostic use at an extremely fast rate (1). There are over 3 million commercially available antibodies; however, in a Nature